At a glance
ClinicalIndex Comparison RecordN/ACompleted· 50 enrolled
Drug / intervention
HTB Rejuvenatedietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Impact of a Polyphenol-Rich Supplement on Epigenetic and Cellular Markers of Immune Age
In Brief
A clinical study evaluating HTB Rejuvenate for Immunity Disorders and 2 related conditions. Completed, enrolled 50 participants across 1 site.
Detailed Summary
This is a prospective, interventional, single-arm, open-label pilot study of 50 patients to evaluate the effect of a polyphenol-rich nutritional supplement on epigenetic and cellular markers of immune age.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsImmunity Disorders, Aging, Inflammation
CountriesUnited States
CollaboratorsTruDiagnostic
Timeline
N/ACompletedFinished
20222023202420252026
First PostedFeb 2022
Enrollment StartMar 2022
Primary CompletionOct 2022
TodayJul 2026
First PostedFeb 10, 2022
Enrollment StartMar 25, 2022
Primary CompletionOct 7, 2022
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 4.4 years ago
Interventions
HTB Rejuvenatedietary
90 days of BID dosing of 2 capsules of HTB Rejuvenate